SLC5A2 and diabetes mellitus: The present multicenter study, registering patients between March 2018 and December 2019, i.e., after the publishment of the potential amputation risk, can show the real-world trends in the prescription of SGLT2 inhibitors in patients with diabetes mellitus undergoing endovascular therapy for symptomatic peripheral artery disease.